XML 17 R6.htm IDEA: XBRL DOCUMENT v3.21.2
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Total
Parent
Common Stock
Common Stock
DeepHealth, Inc.
Additional Paid-In Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Noncontrolling Interests
Beginning balance (in shares) at Dec. 31, 2019     50,314,328          
Beginning balance, value at Dec. 31, 2019 $ 233,139 $ 151,685 $ 5   $ 262,865 $ (8,026) $ (103,159) $ 81,454
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Issuance of common stock under the equity compensation plan (in shares)     416,817          
Stock-based compensation expense 8,136 8,136     8,136      
Issuance of common stock for sale of unregistered securities for the DeepHealth acquisition (in shares)     823,615          
Issuance of common stock for sale of unregistered securities for the DeepHealth acquisition 33,011 33,011     33,011      
Change in cumulative foreign currency translation adjustment (6) (6)       (6)    
Change in fair value of cash flow hedge, net of taxes (18,958) (18,958)       (18,958)    
Change in fair value of cash flow hedge from prior periods reclassified to earnings, net of taxes 892 892       892    
Net (loss) income (22,958) (26,952)         (26,952) 3,994
Ending balance (in shares) at Jun. 30, 2020     51,554,760          
Ending balance, value at Jun. 30, 2020 233,256 147,808 $ 5   304,012 (26,098) (130,111) 85,448
Beginning balance (in shares) at Mar. 31, 2020     50,694,375          
Beginning balance, value at Mar. 31, 2020 207,189 123,375 $ 5   269,461 (26,574) (119,517) 83,814
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Issuance of common stock under the equity compensation plan (in shares)     36,770          
Stock-based compensation expense 1,540 1,540     1,540      
Issuance of common stock for sale of unregistered securities for the DeepHealth acquisition (in shares)     823,615          
Issuance of common stock for sale of unregistered securities for the DeepHealth acquisition 33,011 33,011     33,011      
Change in cumulative foreign currency translation adjustment (7) (7)       (7)    
Change in fair value of cash flow hedge, net of taxes (409) (409)       (409)    
Change in fair value of cash flow hedge from prior periods reclassified to earnings, net of taxes 892 892       892    
Net (loss) income (8,960) (10,594)         (10,594) 1,634
Ending balance (in shares) at Jun. 30, 2020     51,554,760          
Ending balance, value at Jun. 30, 2020 233,256 147,808 $ 5   304,012 (26,098) (130,111) 85,448
Beginning balance (in shares) at Dec. 31, 2020     51,640,537          
Beginning balance, value at Dec. 31, 2020 258,303 165,743 $ 5   307,788 (24,051) (117,999) 92,560
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Issuance of common stock upon exercise of options (in shares)     2,500          
Issuance of common stock upon exercise of options 26 26     26      
Issuance of common stock under the equity compensation plan (in shares)     1,033,358 1,635        
Stock-based compensation expense 17,145 17,145     17,145      
Purchase of noncontrolling interests (4) (4)     (4)      
Contribution from noncontrolling partner 123             123
Change in cumulative foreign currency translation adjustment (21) (21)       (21)    
Change in fair value of cash flow hedge, net of taxes 0              
Change in fair value of cash flow hedge from prior periods reclassified to earnings, net of taxes 1,845 1,845       1,845    
Other 0 (1)     (1)     1
Net (loss) income 21,862 12,331         12,331 9,531
Ending balance (in shares) at Jun. 30, 2021     52,678,030          
Ending balance, value at Jun. 30, 2021 299,279 197,064 $ 5   324,954 (22,227) (105,668) 102,215
Beginning balance (in shares) at Mar. 31, 2021     52,340,856          
Beginning balance, value at Mar. 31, 2021 281,358 184,358 $ 5   316,032 (23,138) (108,541) 97,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Issuance of common stock upon exercise of options (in shares)     2,500          
Issuance of common stock upon exercise of options 26 26     26      
Issuance of common stock under the equity compensation plan (in shares)     333,533 1,141        
Stock-based compensation expense 8,897 8,897     8,897      
Change in cumulative foreign currency translation adjustment (9) (9)       (9)    
Change in fair value of cash flow hedge, net of taxes 0              
Change in fair value of cash flow hedge from prior periods reclassified to earnings, net of taxes 920 920       920    
Other 0 (1)     (1)     1
Net (loss) income 8,087 2,873         2,873 5,214
Ending balance (in shares) at Jun. 30, 2021     52,678,030          
Ending balance, value at Jun. 30, 2021 $ 299,279 $ 197,064 $ 5   $ 324,954 $ (22,227) $ (105,668) $ 102,215